Serum Levels of Chemokine Ligand-7 and Interferon-γ-induced Protein-10: Possible Severity and Prognostic Markers in Patients with COVID-19
Authors:
Open Access
- 1 June 2022
- journal article
- research article
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 16 (2) , 1298-1306
Abstract
Patients with coronavirus disease-19 (COVID-19) present as mildly, moderately, or severely and critically ill. Cytokine storm is responsible for fatal pneumonia and acute respiratory distress syndrome. Interferon-γ-induced protein-10 (IP-10) and chemokine ligand-7 (CCL-7) are chemokines that play a role in the chemotaxis of inflammatory cells and the release of pro-inflammatory cytokines. In this study, we assessed the serum levels of IP-10 and CCL-7 chemokines in COVID-19 patients and their correlation with disease severity and prognosis. The serum levels of CCL-7 and IP-10 were assessed in 67 COVID-19 patients and 10 healthy controls. Serum samples were collected and examined for these two markers using direct enzyme-linked immunosorbent assay. Patients were divided into two groups according to their disease severity. Serum levels of the test markers were compared between patients and controls, and between patients with different disease severities and correlated with other clinical and laboratory parameters. CCL-7 and IP-10 levels were significantly higher in patients than in controls and in severe than in mild/moderate cases. The receiver operating characteristic curve analysis of the two markers showed better performance of the combined markers as predictors of disease severity (area under the curve = 0.792). The results of our study suggest a potential role of IP-10 and CCL-7 as predictors of COVID-19 severity.Keywords
This publication has 21 references indexed in Scilit:
- Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanerceptAnnals of the Rheumatic Diseases, 2020
- Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19Journal of Allergy and Clinical Immunology, 2020
- The pathogenesis and treatment of the `Cytokine Storm' in COVID-19Journal of Infection, 2020
- TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor FedratinibJournal of Microbiology, Immunology and Infection, 2020
- The immunology of COVID-19: is immune modulation an option for treatment?The Lancet Rheumatology, 2020
- COVID-19: a case for inhibiting IL-17?Nature Reviews Immunology, 2020
- Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)Frontiers in Immunology, 2020
- Cytokine-targeted therapy in severely ill COVID-19 patients: Options and cautionsEurasian Journal of Medicine and Oncology, 2020
- Active Replication of Middle East Respiratory Syndrome Coronavirus and Aberrant Induction of Inflammatory Cytokines and Chemokines in Human Macrophages: Implications for PathogenesisThe Journal of Infectious Diseases, 2013
- Expression and function of chemokines during viral infections: from molecular mechanisms to in vivo functionJournal of Leukocyte Biology, 2003